Health Minister Hsueh Jui-yuan (薛瑞元) said Wednesday the ministry's commissioning of Choice Pharma Taiwan to conduct Phase 2 clinical trials of the locally manufactured Medigen COVID-19 vaccine predated a merger between Choice Pharma's parent company and a Shanghai-based firm, amid controversy over possible Chinese involvement in the trials.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Politics
Senior KMT official detained in Pingtung recall forgery case
07/02/2025 02:01 PM - Business
Taiwan shares close up 0.11%
07/02/2025 01:54 PM - Business
Stock trading accounts hit new high despite U.S. tariff concerns
07/02/2025 12:47 PM - Cross-Strait
Taiwan intelligence agency warns of RedNote, TikTok data breaches
07/02/2025 11:58 AM - Business
TSMC Arizona chairman to retire; no successor named yet
07/02/2025 11:12 AM